SEC 13F Intelligence

Managers / Q1 2021 · view latest →

Endurant Capital Management LP

CIK 0001633055 · 66 BOVET ROAD, SUITE 353, SAN MATEO, CA, 94402 · 650-539-5905

Reported Value
$384M
Q1 2021
Positions
61
Filings on Record
24
2019–present window
Filed
May 17, 2021
original filing

Summary

Endurant Capital Management LP reported $384M in U.S.-listed holdings across 61 positions for Q1 2021.

Its largest position, KIDS, represents 5.0% of the portfolio.

Compared with Q4 2020, the fund opened 28 new positions and exited 19.

Portfolio Metrics

Turnover
+34.7%
vs prior filed quarter
Top-10 Concentration
+37.1%
share of reported value
Largest Position
+5.0%
Orthopediatrics
New / Exited
28 / 19
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $189MQ4 ’18Q1 ’19: $253MQ2 ’19: $254MQ3 ’19: $279MQ3 ’19Q4 ’19: $317MQ1 ’20: $221MQ2 ’20: $1.8BQ2 ’20Q3 ’20: $338MQ4 ’20: $277MQ1 ’21: $384MQ1 ’21Q2 ’21: $364MQ3 ’21: $439MQ4 ’21: $414MQ4 ’21Q1 ’22: $380MQ2 ’22: $285MQ3 ’22: $307MQ3 ’22Q4 ’22: $246MQ1 ’23: $195MQ2 ’23: $115MQ2 ’23Q3 ’23: $111MQ4 ’23: $17MQ1 ’24: $0Q1 ’24filingsflow.com

Portfolio Composition

By security type
Common Stock: 76.4%Other: 9.5%ADR: 9.0%US DOMESTIC: 5.0%
  • Common Stock · 76.4% · $293M
  • Other · 9.5% · $37M
  • ADR · 9.0% · $35M
  • US DOMESTIC · 5.0% · $19M

Quarter-over-Quarter Changes full breakdown →

vs Q4 2020 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
INVACARE CORPNEW+19.97M19.97M+$19M$19M
ATNMACTINIUM PHARMACEUTICALS INCNEW+2.00M2.00M+$15M$15M
SNYSANOFINEW+272.2K272.2K+$13M$13M
CVSCVS HEALTH CORPNEW+167.4K167.4K+$13M$13M
IVCUSDINVACARE CORPNEW+1.11M1.11M+$9M$9M
MCKMCKESSON CORPNEW+44.1K44.1K+$9M$9M
BUWABIO RAD LABS INCNEW+14.8K14.8K+$8M$8M
PHASEURPHASEBIO PHARMACEUTICALS INCNEW+2.16M2.16M+$7M$7M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2021

48 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1IVCUSDINVACARE CORPNOTE 5.000%11/1 · COM7.35%$28M21.07M
2KIDSORTHOPEDIATRICS CORPhistory →COM5.04%$19M396.2K
3BMYBRISTOL-MYERS SQUIBB COhistory →COM3.85%$15M233.9K
4AHCOADAPTHEALTH CORPhistory →COM CL A3.83%$15M399.7K
5SNYSANOFIhistory →SPONSORED ADR3.51%$13M272.2K
6BDXBECTON DICKINSON & COhistory →COM3.45%$13M54.4K
7CVSCVS HEALTH CORPhistory →COM3.28%$13M167.4K
8AZNNASTRAZENECA PLChistory →SPONSORED ADR3.09%$12M238.1K
9LABORATORY CORP AMER HLDGSCOM NEW3.01%$12M45.2K
10ACRSACLARIS THERAPEUTICS INChistory →COM2.99%$11M455.4K
11ELVANTHEM INChistory →COM2.98%$11M31.8K
12EHCENCOMPASS HEALTH CORPhistory →COM2.86%$11M133.8K
13IOVAIOVANCE BIOTHERAPEUTICS INChistory →COM2.56%$10M310.6K
14ABBVABBVIE INChistory →COM2.48%$10M88.0K
15MOLECULAR TEMPLATES INCCOM2.33%$9M709.4K
16MCKMCKESSON CORPhistory →COM2.24%$9M44.1K
17BUWABIO RAD LABS INChistory →CL A2.20%$8M14.8K
18ELUTAZIYO BIOLOGICS INChistory →COM CL A2.10%$8M583.6K
198INSYNEOS HEALTH INChistory →CL A2.09%$8M105.5K
20PHASEURPHASEBIO PHARMACEUTICALS INChistory →COM1.95%$7M2.16M
21ABGAMERISOURCEBERGEN CORPhistory →COM1.93%$7M62.7K
22OCULOCULAR THERAPEUTIX INChistory →COM1.88%$7M438.9K
23AVTRAVANTOR INChistory →COM1.82%$7M241.0K
24BSXBOSTON SCIENTIFIC CORPhistory →COM1.60%$6M158.7K
25DRIOEURDARIOHEALTH CORPhistory →COM NEW1.60%$6M317.9K
26GDRXGOODRX HLDGS INChistory →COM CL A1.39%$5M136.5K
27TREURTRILLIUM THERAPEUTICS INChistory →COM NEW1.34%$5M478.4K
28CNCCENTENE CORP DELhistory →COM1.28%$5M76.6K
29ADAPYADAPTIMMUNE THERAPEUTICS PLChistory →SPONDS ADR1.27%$5M915.7K
30JNJJOHNSON & JOHNSONhistory →COM1.24%$5M28.9K
31MREOMEREO BIOPHARMA GROUP PLChistory →ADS1.18%$5M1.34M
32IM8NINSMED INChistory →COM PAR $.011.18%$5M132.4K
33SELECTA BIOSCIENCES INCCOM1.08%$4M911.7K
34CALLIDITAS THERAPEUTICS ABSPONSERED ADS1.02%$4M142.3K
35RGLSUSDREGULUS THERAPEUTICS INCCOM NEW0.97%$4M2.38M
36BDQMALBIREO PHARMA INCCOM0.95%$4M103.2K
37MEDAVAIL HOLDINGS INCCOM0.84%$3M229.8K
38APTOSE BIOSCIENCES INCCOM NEW0.81%$3M517.5K
39SEELOS THERAPEUTICS INCCOM0.80%$3M611.6K
40ANGOANGIODYNAMICS INCCOM0.79%$3M128.9K
41ZTSZOETIS INCCL A0.73%$3M17.7K
42RCMEURR1 RCM INCCOM0.70%$3M108.2K
43AFFIMED N VCOM0.68%$3M330.7K
44TRLDAVITA INCCOM0.67%$3M23.9K
45ACHOWENS & MINOR INC NEWCOM0.63%$2M64.0K
46GEMINI THERAPEUTICS INCCOM0.60%$2M169.9K
47VTLUSDIMMUNIC INCCOM0.55%$2M131.8K
48MRVIMARAVAI LIFESCIENCES HLDGS ICOM CL A0.54%$2M58.2K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2024$01May 7, 202413F-HRchanges · EDGAR ↗
Q4 2023$17M25Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$111M43Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$115M34Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$195M50May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$246M55Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$307M49Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$285M50Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$380M63May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$414M68Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$439M53Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$364M57Aug 27, 2021RESTATEMENTchanges · EDGAR ↗
Q1 2021$384M61May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$277M52Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$338M60Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$1.8B56Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$221M51May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$317M54Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$279M49Nov 25, 2019RESTATEMENTchanges · EDGAR ↗
Q2 2019$254M50Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$253M70May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$189M48Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.